News | November 03, 2021
Venus Remedies H1 net profit rises 315%
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Key takeaways of recent quarter & conference call highlights
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Subscribe To Our Newsletter & Stay Updated
